Gene Test Identifies Breast Cancer Patients Who Can Safely Skip Chemotherapy
Findings from the OPTIMA trial show that the Prosigna test identifies patients who can safely skip chemotherapy and use hormone therapy alone.
Category: Breast
Breast
Latest
Breast
Latest
New AI Test Estimates Individualized Chemotherapy Benefit in Breast Cancer Patients
Using causal artificial intelligence and digital pathology, the test moves beyond population-level averages to predict patient-specific chemotherapy outcomes.
Breast
Latest
PreciseDx Presents Validation Data for AI Breast Cancer Recurrence Test
Three abstracts showcase PreciseBreast's ability to predict recurrence risk in early-stage invasive breast cancer using digital pathology.
Blood Test Achieves 85% Accuracy in Predicting Breast Cancer Immunotherapy Response
Researchers develop PIPscore using plasma proteomics to identify triple-negative breast cancer patients most likely to benefit from immunotherapy treatment.
Read More
Test Gains Medicare Coverage for Early-Stage Breast Cancer Recurrence Monitoring
Coverage marks a step in expanding access to ultra-sensitive molecular residual disease detection for breast cancer patients.
Read More
A Precision Oncology Approach Calls for Regular ESR1 Monitoring
Emerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.
Read More
PREDICT DNA and SCANDARE Study Results Unveiled
Personalis, Inc. unveiled promising new clinical data from the PREDICT DNA and SCANDARE studies at ASCO 2025.
Read More
MRD Detection Gets New Standard with Pathlight
SAGA Diagnostics has launched Pathlight, a groundbreaking multi-cancer blood test for ultra-sensitive detection of MRD.
Read More
Breast Cancer Index Test Data Reinforces Efficacy
Hologic and Biotheranostics unveiled new data showing that the Breast Cancer Index (BCI) test improves treatment decision-making.
Read More
Study IDs Two New Breast Cancer Genes in Black Women
A groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.
Read More
Ibex Breast Demonstrates High Accuracy, Efficiency in Study
A new peer-reviewed study confirms that Ibex Breast significantly enhances accuracy, speed, and efficiency of breast pathology evaluations.
Read More
Rethinking Breast Cancer Screening
A new editorial discusses findings from the COMET trial, suggesting that early-stage breast cancer may not require immediate surgery.
Read More
HER2-ultralow Metastatic Breast Cancer Companion Diagnostic Approved by FDA
Roche’s PATHWAY anti-HER2/neu (4B5) test has received FDA approval to ID patients with HR-positive, HER2-ultralow metastatic breast cancer.
Read More
BioView Unveils Breakthrough Liquid Biopsy for HER2 Detection in Metastatic Breast Cancer
BioView’s liquid biopsy test offers a non-invasive method to detect HER2 status in metastatic breast cancer patients.
Read More
AI-Powered Blood Test Spots Earliest Sign of Breast Cancer
A new laser analysis and AI method capable of detecting stage 1a breast cancer with 98% accuracy offers an effective screening option.
Read More
New Genetic Breast Cancer Model Developed
A researcher’s new mouse model for studying breast cancer could enhance understanding of cancer metastasis and its spread to organs.
Read More
Alverno Labs Expands Practice of Ibex’s AI-Powered Cancer Diagnostics Platform
Alverno Laboratories has expanded its use of Ibex’s AI-powered cancer diagnostics platform to include breast cancer detection for patients.
Read More
Ibex Unveils Advancements in AI Breast Cancer Diagnostics Platform
Ibex has introduced advancements to its AI-powered platform, enhancing breast cancer diagnostics, improving algorithm accuracy, and more.
Read More